BioCryst Pharmaceuticals (BCRX) said Friday that Colombia's National Institute of Drug and Food Surveillance has approved Orladeyo to prevent hereditary angioedema attacks in patients at least 12 years old.
The company said it has an exclusive collaboration with Pint Pharma for Orladeyo in the pan-Latin America region, with Pint in charge of all marketing authorizations and commercialization in the region.
Orladeyo has also been approved in Chile, Argentina, Brazil, Mexico and Peru, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.